瘤治疗场 (TTFields) 的选择性抗瘤活性涉及癌细胞和瘤微环境中的分子因素
Ilaria Fuso Nerini1, Rosy Amodeo2, Maurizio D'Incalci2
1Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Translational oncology
|October 1, 2025
概括
瘤治疗场 (TTFields) 在癌症治疗中表现有前途. 本综述探讨了影响TTFields的细胞因素.
科学领域:
- 在瘤学瘤学.
- 生物物理学的生物物理.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 以中频率的低强度电场,称为瘤治疗场 (TTFields),是一种新兴的抗癌治疗方法.
- 对于各种固体瘤,TTFields在与化疗和免疫治疗相结合时是有效的.
- 决定瘤对TTFields敏感性的细胞和遗传因素尚不清楚.
研究的目的:
- 对影响TTFields抗癌性能的细胞因素的临床前和转化研究进行全面审查.
- 分析揭示TTFields治疗潜力的作用机制的OMICS研究.
- 确定与抗癌药物联合治疗的协同策略.
主要方法:
- 系统审查临床前和转化研究.
- 从TTFields研究中分析omics数据.
- 文献综述侧重于细胞和分子过程.
主要成果:
- 确定了影响TTFields疗效的关键细胞因素.
- 突出显示复杂的细胞和分子对TTFields的反应.
- 揭示了TTFields在调节瘤微环境和逆转免疫抑制方面的潜力.
结论:
- 了解细胞决定因素对于优化TTFields疗法至关重要.
- TTFields调节瘤微环境和免疫反应的能力提供了一个有希望的策略.
- 对TTFields机制的进一步研究可以导致合理的联合治疗设计,以提高免疫疗法的疗效.
相关概念视频
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


